Literature DB >> 346216

Amputation and adriamycin in primary osteosarcoma: a 5-year report.

E P Cortes, J F Holland, O Glidewell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 346216

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  8 in total

Review 1.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

2.  Adjuvant systemic therapy after ablative surgery for limb osteosarcoma.

Authors:  B M Cantwell; J J Fennelly; M P Jones
Journal:  Ir J Med Sci       Date:  1982-12       Impact factor: 1.568

3.  The therapy of osteosarcoma by intraarterial cis-platinum an limb preservation.

Authors:  V P Chuang; S Wallace; R S Benjamin; N Jaffe; A Ayala; J Murray; J Zornoza; Y Patt; G Mavligit; C Charnsangavej; C S Soo
Journal:  Cardiovasc Intervent Radiol       Date:  1981       Impact factor: 2.740

Review 4.  Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

Authors:  V B Pai; M C Nahata
Journal:  Drug Saf       Date:  2000-04       Impact factor: 5.606

Review 5.  Adjuvant and Neoadjuvant Chemotherapy for Osteosarcoma: A Historical Perspective.

Authors:  Robert S Benjamin
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.

Authors:  M H Bronchud; A Howell; D Crowther; P Hopwood; L Souza; T M Dexter
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

7.  A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Authors:  E F Smit; H H Berendsen; D A Piers; J Smeets; A Riva; P E Postmus
Journal:  Br J Cancer       Date:  1992-03       Impact factor: 7.640

8.  Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).

Authors:  G Colucci; S Romito; V Gebbia; G Pacilio; F Giotta; A Testa; G Pezzella; E Durini; B Agostara; S Cariello
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.